Mexico’s Supreme Court has upheld a 2010 resolution by the Federal Competition Commission (Now COFECE), which imposed sanctions for up to 21 million pesos on several pharmaceutical companies accused of price fixing.
The companies have been accused of coordinating to manipulate the prices in contests for the provision of insulin, electrolyte and saline solution to Mexico’s national health service. The decision marks the first time the court has confirmed the existence of absolute monopolistic behavior.
The court upheld the validity of the economic analysis used to determine the existence price-fixing agreements between the companies, and whether these agreements had negatively affected the market dynamics, equilibrium, or otherwise been detrimental to competition.
Full content: El Diario
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI